Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sunitinib malate, quantity: 33.412 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: iron oxide yellow; mannitol; croscarmellose sodium; titanium dioxide; iron oxide red; gelatin; pregelatinised maize starch; magnesium stearate; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib msn is indicated for;,treatment of advanced renal cell carcinoma (rcc),treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 60 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 40 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 20 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression. sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 10 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: magnesium stearate; titanium dioxide; croscarmellose sodium; microcrystalline cellulose; methacrylic acid copolymer; colloidal anhydrous silica; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); gelatin; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: purified talc; microcrystalline cellulose; gelatin; croscarmellose sodium; titanium dioxide; triethyl citrate; colloidal anhydrous silica; magnesium stearate; methacrylic acid copolymer; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); croscarmellose sodium; methacrylic acid copolymer; purified talc; titanium dioxide; gelatin; triethyl citrate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: gelatin; purified talc; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; triethyl citrate; methacrylic acid copolymer; titanium dioxide; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - dimethyl fumarate msn is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - erlotinib hydrochloride, quantity: 109.267 mg (equivalent: erlotinib, qty 100 mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hyprolose; lactose monohydrate; microcrystalline cellulose; hypromellose; sodium lauryl sulfate; sodium starch glycollate - non-small cell lung cancer,erlotinib arx is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations.,erlotinib arx is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy.,erlotinib arx is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer,erlotinib arx in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.